anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants who enter the this open-label extension study immediately after completing Double-blind Phase Study R092670PSY3015 (previous study) will receive Paliperidone Palmitate 6 month (PP6M) intramuscular (IM) injections, dose will be selected based on the unblinded dose level ("moderate" or "higher") that the participant received during previous study. Participants in the "moderate" dose level will receive PP6M Dose 1 and "higher" dose level will receive PP6M Dose 2 during the open-label extension. The PP6M dose level may be adjusted (to Dose 1 or Dose 2) for every 6 month at Visits 3, 5, and 7, based on clinical judgment. Participants who enter this open-label extension study later (up to 3 months after they complete previous study) and were on a moderate or higher dose of PP3M (350 or 525 mg eq.) or PP1M (100 or 150 mg eq.) will receive initial dose of PP6M IM injection (Dose 1 or Dose 2) for every 6 months.
PURPOSE:To obtain the subject contoxic treating agent of arthrosis deformans showing excellent interleukin production and release inhibition, etc., and having a protective effect of arthrodial cartilage by blending catechol derivatives as the active component. CONSTITUTION:One or more of catechol derivatives of the formula (R is H or acyl; X is CHO, COOH, etc.) are used as the active components. As the compound of the formula, e.g. 3,4-diacetoxybenzylidene acetate is exemplified. The compound of the formula may be used by itself or in a form of a mixture with a diluent and other agents. The compound of the formula can be contained in the above mentioned drug in a wide range of 0.01-100wt.%, preferably 0.1-70wt.%.
The safety and effectiveness of ALVAIZ have been established in pediatric patients 6 years and older with persistent or chronic ITP. 

The safety and effectiveness of eltrombopag in pediatric patients 6 years and older with persistent or chronic ITP were evaluated in two double-blind, placebo-controlled trials [see Adverse Reactions (6.1), Clinical Studies (14.1)]. The pharmacokinetics of eltrombopag have been established in 130 pediatric patients 6 years and older with ITP dosed once daily [see Clinical Pharmacology (12.3)]. See Dosage and Administration (2.1) for dosing recommendations for pediatric patients 6 years and older.

The safety and effectiveness of ALVAIZ have not been established in pediatric patients less than 6 years of age with persistent or chronic ITP. Pediatric patients must be able to swallow ALVAIZ tablets whole [see Dosage and Administration (2.5)].

The safety and effectiveness in pediatric patients with thrombocytopenia associated with chronic hepatitis C and refractory severe aplastic anemia have not been established.
A combination comprising: (a) a therapeutically-effective amount of at least one compound which is: or a pharmaceutically acceptable salt thereof; (b) a hormone ablation agent; and (c) a therapeutically-effective amount of an additional therapeutic agent selected from the group consisting of an anti-androgen agent, docetaxel, and prednisone; for use in the treatment of a refractory prostate cancer in a subject in need thereof. In another aspect, the same combination is used to treat and androgen-dependent disorder. Preferably, the hormone ablation agent is selected from the group consisting of deslorelin, leuprolide, goserelin, and triptorelin. Preferred anti-androgen agents are selected from the group consisting of bicalutamide, flutamide, spironolactone, cyproterone acetate, finasteride, dutasteride, and nilutamide. More, preferably, the anti-androgen agent is bicalutamide or flutamide and the hormone ablation agent is leuprolide. The compound of formula I is also known as galeterone.
A contact lens fluid delivery device having a liquid reservoir connected to a channel with a flow regulator is described. Other eye hydration and variable dioptric power contact lenses are described herein. Also described are implantable liquid delivery apparatuses having a liquid storage reservoir connected to a channel with a flow regulator. These devices and apparatuses are useful for specific, targeted delivery of therapeutic liquids within a subject. In some embodiments, the devices incorporate actuation chambers which provide a driving force releasing the fluid into the targeted area e.g., the eye. The actuation chambers described herein can contain phase change materials or osmotic chambers or a combination thereof to drive the release of fluid.
This pilot study will assess the effects of doxazosin on objective measures of sleep in PTSD subjects using home ambulatory polysomnography. Twenty (20) men and women with chronic PTSD will be enrolled at the San Francisco Veterans Affairs Medical Center. After initial screening, subjects will complete 1 week of baseline assessments including 2 nights of home ambulatory polysomnography. They will then participate in a 2-week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment ending with 2 nights of home polysomnography. Subjective and rater-based assessments will be conducted at baseline and at set intervals during and at the end of treatment. Wrist actigraphy measurements will also be made at baseline and at end of treatment as an economical, fairly valid and unobtrusive measure of sleep duration. We hypothesize that doxazosin will be associated with an increase in total sleep time (TST) and a decrease in wake time after sleep onset (WASO). We hypothesize that doxazosin will also be associated with clinical gains with respect to nightmares, subjective sleep quality, non-sleep PTSD symptoms, depression symptoms, and quality of life.
PURPOSE:To obtain the titled composition having extremely excellent stability of active vitamin D3 and useful as a remedy for osteopathy such as osteomalacia, osteoporosis, etc., by dissolving an active vitamin D3 compound in triacetin. CONSTITUTION:The titled composition having remarkably improved stability can be produced by dissolving an active vitamin D3 compound (e.g. 1alpha- hydroxyvitamin D3, 1alpha,25-dihydroxyvitamin D3, etc.) in triacetin. The dissolution can be carried out either by adding the active vitamin D3 compound to triacetin as it is, or by dissolving the active vitamin D3 in an organic solvent such as ethanol, adding the solution to triacetin and distilling out the organic solvent. It can be administered in the form of soft capsule, subcutaneous injection or intramuscular injection.
The efficacy of alprazolam in the treatment of panic disorder was demonstrated in three short-term (up to 10 weeks), randomized, double-blind, placebo-controlled studies. Patients in the studies had diagnoses corresponding closely to DSM-III-R criteria for panic disorder (with or without agoraphobia). 

The average dose of alprazolam was 5 mg to 6 mg per day in two of the studies, and the doses of alprazolam were fixed at 2 mg and 6 mg per day in the third study. In all three studies, alprazolam was superior to placebo on a variable defined as "the number of patients with zero panic attacks" (range, 37 to 83% met this criterion), as well as on a global improvement score. In two of the three studies, alprazolam was superior to placebo on a variable defined as "change from baseline on the number of panic attacks per week" (range, 3.3 to 5.2), and also on a phobia rating scale. A subgroup of patients who were improved on alprazolam during short-term treatment in one of these trials was continued on an open basis up to 8 months, without apparent loss of benefit.
This group will be randomized to wait list control. They will serve as a control for the intervention at time points 1 and 2. However after a 2-3 month period they will receive the intervention.
The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. They include nausea, vomiting, abdominal pain, diarrhea and anorexia. Symptoms of hepatic dysfunction and/or abnormal liver-function test results may occur (see WARNINGS section). Pseudomembranous colitis has been rarely reported in association with erythromycin therapy.

Allergic reactions ranging from urticaria and mild skin eruptions to anaphylaxis have occurred.

There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal insufficiency and in patients receiving high doses of erythromycin.

Onset of pseudomembranous colitis symptoms may occur during of after antibiotic treatment. (See WARNINGS.)
A composition which helps reduce joint inflammation and structural damage to joints during the growth of muscle structure, whether such growth is for repair of damaged muscle tissue or for development of new and enhanced muscular structure. The composition comprises a combination of edible nutritional protein, and a hyperimmune milk protein concentrate. The preferred nutritional protein is a whey protein isolate. The concentration of nutritional protein present in the composition typically ranges from about 10% by weight to about 90% by weight, more typically about 70% by weight to about 90% by weight. The composition may contain additional ingredients such as polypeptides, amino acids, antioxidants and various flavorings and sweeteners. A method of use of the composition is also disclosed.
The invention discloses a wine having effects of reinforcing bone and relaxing muscles and tendons. The wine is prepared from 15-25g of eucommia ulmoides, 15-25g of teasel root, 15-25g of cyathula root, 15-25g of rhizoma cibotii, 15-25g of parasitic loranthus, 15-25g of sappan wood, 15-25g of ground beetle, 15-25g of frankincense, 15-25g of myrrh, 15-25g of barbary wolfberry fruit, 15-25g of chrysanthemum, 15-25g of ligusticum wallichii, 15-25g of malaytea scurfpea fruit, 15-25g of lumbricus, 240-260g of brown sugar, 240-260g of white sugar and 1000ml of liquor having alcoholic strength more than 56 degrees. According to the theory of traditional Chinese medicine, backache is caused by kidney deficiency, weakness, qi stagnation and blood stasis, and eucommia ulmoides, teasel root, rhizoma cibotii, parasitic loranthus and barbary wolfberry fruit have effects of reinforcing bone and tonifying kidney and sappan wood and ground beetle are used. Frankincense, myrrh, ligusticum wallichii and malaytea scurfpea fruit have effects of invigorate blood circulation and relaxing muscles and tendons. Musk has effects of relieving pain and removing blood stasis. Liquor can promote dissolution and absorption of medicines. Brown sugar, white sugar and chrysanthemum can ease medicine properties. The wine can promote waist blood circulation, accelerate inflammation absorption and improve functions of waist and back muscle and ligament. Through cooperation of the above medicines, the wine has substantial curative effects on soreness of waist and backache and has no side effects.
The incidence and recent trends of candidemia and the contribution of the COVID-19 pandemic to its evolution are not well documented. The catheter is a major focus of Candida spp. infections, but the methods used to confirm the origin of candidemia are still based on the data generated for bacterial infection. The presence of Candida spp. on the tip of a removed catheter is the gold standard for confirmation but it is not always possible to remove it. Conservative methods, without catheter removal, have not been specifically studied for microorganisms whose times of growth are different from those of bacteria and therefore these results are not applicable to candidemia. The different Candida species do not have a particular tropism for catheter colonization and fungal biomarkers have not yet been able to contribute to the determination of the origin of candidemia. Techniques such Candida T2 Magnetic Resonance (T2MR) has not yet been applied for this purpose. Finally, there is not yet a consensus of how to proceed when Candida spp. is isolated from an extracted catheter and blood cultures obtained from simultaneous peripheral veins are negative. In this lack of firm data, a group of experts has formulated a series of questions trying to answer them based on the literature, indicating the current deficiencies and offering their own opinion. All authors agree with the conclusions of the manuscript and offer it as a position and discussion paper.
A medical effector system comprises a) a microprocessor-based bedside monitoring unit; b) a microprocessor-based procedure room and C) an umbilical cable. The microprocessor-based bedside monitoring unit has a bedside-monitoring unit host controller, has a first series of connection points for receiving patient inputs from patient monitoring connections has a second series of connection points for outputting patient outputs based on the received inputs, and has a display screen for displaying at least some of the patient outputs. a microprocessor-based procedure room unit having a medical effector, and The microprocessor-based procedure room has a medical effector, has a drug-delivery flow control assembly and a procedure-room-unit host controller with a memory containing a patient-monitoring and end-effector-scheduling program which is operatively connected to program inputs based at least in part on at least some of the patient outputs and controls, and/or advises a user to control, the medical effector based at least in part on the program inputs. The procedure room unit (PRU) has an individual PRU identifier and the bedside monitoring unit (BMU) has an individual BMI identifier. The umbilical cable has a first end attached or attachable to the second series of connection points of the bedside monitoring unit and has a second end attached or attachable to the procedure room unit. At least one of the first and second ends is detachable from the corresponding bedside monitoring unit or the procedure room unit, and the procedure-room-unit host controller and the bedside-monitoring unit host controller are operatively connected together when the umbilical cable is attached to the procedure room unit and the bedside monitoring unit.
BACKGROUND AND OBJECTIVE: Impulse control disorders (ICD), psychosis and delirium are part of the spectrum of behavioural changes associated with Parkinson's disease (PD). The diagnostic and therapeutic management of these rather complex neuropsychiatric conditions has been updated in the clinical guideline by the German Society of Neurology (DGN).
METHODS: Recommendations are based on a systematic literature reviews, other relevant guidelines and expert opinion.
RESULTS: Patients receiving dopamine agonists (DA) therapy should be informed about the symptoms and risks of an ICD and should be routinely screened for ICD symptoms. In the presence of an ICD, DA should be reduced or discontinued and psychotherapeutic treatment may be considered. Non-oral therapies (levodopa/carbidopa intestinal gel infusion or deep brain stimulation) may also be an option for appropriate candidates. Psychosis in PD often has a gradual onset. Cognitive and affective disorders, psychiatric and medical comorbidities as well as polypharmacy are risk factors for a psychosis. Non-pharmacological treatments should be implemented as soon as possible and anti-parkinsonian medications should be adjusted/reduced if feasible. For psychosis associated with PD, quetiapine or clozapine should be used on an as-needed basis and for as short a time as is necessary, with safety monitoring. Delirium in PD may be underdiagnosed due to an overlap with chronic neuropsychiatric features of PD. Although transient by definition, delirium in PD can lead to permanent cognitive decline, motor impairment and increased mortality. Management of delirium includes pharmacological and non-pharmacological interventions.
CONCLUSION: The updated guideline encompasses the evidence-based diagnostic, non-pharmacological and pharmacological management of ICD, psychosis and delirium in PD.
Subjects initially randomized to apremilast 30 mg twice a day, and who demonstrate a PASI 75 response at Week 32 will be randomized (1 to 1) to either continue to receive apremilast 30 mg ) BID or to receive placebo (until effect is lost). At the time effect is lost, subjects will be treated with apremilast 30 mg twice a day for the duration of their participation in the study.
Completed log that indicated time of eating dinner; weekly blood pressure measurements for the 6 week intervention; control participants also turned in dinner time logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
Long-term ganciclovir maintenance therapy has been recommended for CMV colitis or esophagitis following induction treatment. Oral ganciclovir is a likely candidate for maintenance because of its possible therapeutic value and ease of administration, but an optimum dose has not been determined. Since oral ganciclovir has a low bioavailability and is more soluble in an acid pH environment, the addition of glutamic acid hydrochloride may enhance gastrointestinal absorption of this drug.

All patients receive an induction regimen of IV ganciclovir administered twice daily for 21 to 42 (Per Amendment 3/4/95) days. A permanent venous catheter is implanted for the induction therapy. If clinically improved following induction, patients are then randomized to receive one of three doses of oral ganciclovir, given first without and then with oral glutamic acid hydrochloride, every 8 hours until they reach a steady state. PER AMENDMENT 3/14/95: After subjects have reached steady state with oral ganciclovir and glutamic acid hydrochloride then PK samples will be taken. Subjects will continue the dosing regimen they were assigned to (glutamic acid hydrochloride will be added if it resulted in at least 33% increased bioavailability) for up to 12 months or until relapse of CMV GI disease is documented. Subjects will be followed at monthly intervals for safety evaluation and for evidence of CMV GI relapse. Subjects who have clinical symptoms of relapse will undergo repeat endoscopy or colonoscopy to document the relapse.
Chronic heart failure (CHF) combined with hyperuricemia (HUA) is a comorbidity that is hard to diagnose by a single biomarker. Exosomal miRNAs are differentially expressed in cardiovascular diseases and are closely associated with regulating most biological functions. This study aimed to provide evidence for miRNA as a new molecular marker for precise diagnosis of the comorbidity of CHF with HUA and further analyze the potential targets of differentially expressed miRNA. This controlled study included 30 CHF patients combined with HUA (Group T) and 30 healthy volunteers (Group C). 6 peripheral blood samples from Group T and Group C were analyzed for exosomal miRNAs by high-throughput sequencing and then validated in the remaining 24 peripheral blood samples from Group T and Group C by applying real-time PCR (RT-PCR). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using R software to predict the differential miRNAs' action targets. 42 differentially expressed miRNAs were detected (18 upregulated and 24 downregulated), in which miR-27a-5p was significantly upregulated (P<0.01), and miR-139-3p was significantly downregulated (P<0.01) in Group T. The combination of miR-27a-5p and miR-139-3p predicted the development of CHF combined with HUA with a maximum area under the curve (AUC) of 0.899 (95 % CI: 0.812-0.987, SEN=79.2 %, SPE=91.7 %, J value = 0.709). GO and KEGG enrichment analysis revealed that the differentially expressed miRNAs had a role in activating the AMPK-mTOR signaling pathway to activate the autophagic response. Collectively, our findings suggest that upregulated exosomal miR-27a-5p combined with downregulated exosomal miR-139-3p can be used as a novel molecular marker for precise diagnosis of CHF combined with HUA and enhanced autophagy by AMPK-mTOR signaling pathway may be one pathogenesis of the differentially expressed miRNAs.
S-salicylyl-N-acetylcysteine of formula (I) is prepared by reacting N-acetylcystine and salicylic acid as in the following, (A), The reactive deriv. selected from the salts of acetylsalicylic acid or mixed anhidrides is reacted with ethylchloroformate. (B), This product is reacted with N-acetylcysteine at low temp. in the presence of organic or inorganic base.  (C), After the produced thioester is isolated, this is converted to their organic or inorganic salts in the hydrophillic, alcoholic or ketonic solvents.  In (I), X is hydrogen, alkali metal, alkali earth metal or organic base.  (I) is useful for antipyretics, antiinflammatories, analgesics and mucolytics.
OBJECTIVES: Delirium is a common post-cardiac surgery complication that presents as acute changes in mental abilities with confused thinking and a lack of awareness of the surroundings. Delirium symptoms present in hyperactive- and hypoactive forms. Hypoactive delirium is often overlooked. Although nursing interventions are important in preventing and treating hypoactive delirium, studies focusing on nurses' experiences of hypoactive delirium are scarce. This study describes registered nurses' experiences of caring for patients with hypoactive delirium after cardiac surgery.
RESEARCH METHODOLOGY/DESIGN: This was a qualitative descriptive study with an inductive approach. Data was collected through focus group interviews with 12 registered nurses with experience in caring for cardiac surgery patients with hypoactive delirium. The study complied with the Consolidated Criteria for Reporting Qualitative Research.
SETTING: A cardiac surgery department at a Swedish University Hospital.
FINDINGS: The analysis resulted in one main category; "Navigating the complexities of care when caring for patients with hypoactive delirium" and three sub-categories: "Challenges, "Nursing interventions" and "Promoting a team approach".
CONCLUSION: Delirium assessment and nursing interventions are perceived as essential yet demanding. when caring for patients with hypoactive delirium. Nursing interventions like maintaining the circadian rhythm and offering emotional support need to be prioritised by the nurses, in line with the autonomy of the registered nurse's profession. Moreover, the team around the patient is crucial for detecting and treating hypoactive delirium, and it is important to involve other professionals as well as the patient's relatives. Future research is needed to develop assessment instruments that more accurately capture hypoactive delirium in the postoperative setting.
IMPLICATIONS FOR CLINICAL PRACTICE: Despite the use of screening tools, nurses still experience challenges in detecting the symptoms of hypoactive delirium, indicating a need for more clinically effective screening tools for hypoactive delirium. Nursing interventions are emphasised in the care of patients with hypoactive delirium.
Elevated Liver Enzymes

Levonorgestrel and ethinyl estradiol tablets, and ethinyl estradiol tablets are contraindicated in women with acute viral hepatitis or severe (decompensated) cirrhosis of the liver [see Contraindications (4)]. Acute liver test abnormalities may necessitate the discontinuation of Jaimiess until the liver tests return to normal and Jaimiess causation has been excluded. Discontinue Jaimiess if jaundice develops.

Liver Tumors

Levonorgestrel and ethinyl estradiol tablets, and ethinyl estradiol tablets are contraindicated in women with benign or malignant liver tumors [see Contraindications (4)]. COCs increase the risk of hepatic adenomas. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death from abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (> 8 years) COC users. The attributable risk of liver cancers in COC users is less than one case per million users.